Valuation: SANA AB

Market Cap 1.59B 156M 143M 132M 119M 224M 14.6B 233M 629M 7.88B 586M 574M 24.89B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.59B 156M 143M 132M 119M 224M 14.6B 233M 629M 7.88B 586M 574M 24.89B EV / Sales 2026 *
15.4x
EV / Sales 2027 * 7.61x
Free-Float
92.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week-3.92%
Current month+3.59%
1 month+14.05%
3 months-9.85%
6 months-13.05%
Current year-45.61%
1 week 11.51
Extreme 11.51
12.94
1 month 10.1
Extreme 10.1
12.94
Current year 8.52
Extreme 8.525
28.3
1 year 8.52
Extreme 8.525
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 28/02/2025
Chief Executive Officer 66 29/04/2022
Chief Tech/Sci/R&D Officer 68 31/12/2013
Director TitleAgeSince
Chairman 71 29/04/2022
Director/Board Member 68 31/12/2014
Director/Board Member 46 18/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Buy

Chairman

84,317 0.0611%
09/09/26 Buy

Chairman

50,000 0.0362%
01/09/26 Buy

Founder

9,000 0.0065%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%-3.92%-29.18%+74.17% 156M
-1.34%-3.09%+56.10%+68.83% 65.45B
+0.59%-1.83%+8.98%+90.01% 58.93B
+0.54%+0.45%+25.96%+87.77% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
-0.17%-1.83%+82.46%+57.69% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -1.09%-3.46%+27.83%+159.36% 40B
Weighted average by Cap. -0.83%-3.29%+34.15%+143.39%

Financials

2026 *2027 *
Net sales 103M 10.12M 9.23M 8.54M 7.7M 14.51M 946M 15.08M 40.75M 511M 37.98M 37.18M 1.61B 209M 20.54M 18.73M 17.32M 15.63M 29.44M 1.92B 30.6M 82.7M 1.04B 77.06M 75.45M 3.27B
Net income - -
Net Debt - -
Projected Income Statement - Annual - SANA AB
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
18/11/26 SEK 11.53 -2.21% 215,256
17/11/26 SEK 11.79 -3.12% 412,287
16/11/26 SEK 12.17 +2.18% 668,596
13/11/26 SEK 11.91 +0.59% 333,300
12/11/26 SEK 11.84 -1.33% 212,984

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - SANA AB
  1. Stock Market
  2. Stocks
  3. SANION Stock